The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.

Josefina Durán, Bernard Combe, Jingbo Niu, Nathalie Rincheval, Cécile Gaujoux-Viala, David T Felson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    OBJECTIVE: To evaluate whether patients with RA who belong to the spectrum of fibromyalgic RA (FRA) have an impaired response to treatment measured by traditional activity scores. METHODS: Patients from the ESPOIR cohort were analysed. This prospective cohort included 813 patients with early arthritis not initially receiving DMARDs. Among the 697 patients who met RA classification criteria, we studied two groups, one with and the other without FRA. The following endpoints were compared at 6, 12 and 18 months using a mixed linear regression model: 28-joint DAS (DAS28), Simple Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and HAQ. In addition, attainment of low disease activity (LDA; DAS28
    Original languageEnglish
    Pages (from-to)2166-2170
    Number of pages4
    JournalRheumatology (Oxford, England)
    Volume54
    Issue number12
    DOIs
    Publication statusPublished - 2015

    Keywords

    • DMARDs
    • disease activity scores
    • early rheumatoid arthritis
    • fibromyalgia
    • fibromyalgic RA
    • outcome measures
    • rheumatoid arthritis
    • therapy
    • treat to target

    Fingerprint

    Dive into the research topics of 'The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.'. Together they form a unique fingerprint.

    Cite this